Brugada Syndrome: The ECG Pattern Behind Unexplained Sudden Cardiac Death, and What Makes It Preventable

The Scene

Note: The following is a HIPAA-clean composite constructed from published case series and clinical patterns. It does not represent a single identifiable patient.

The call comes in at 3:14 AM. A 34-year-old man, Southeast Asian descent, is brought in by ambulance after his wife found him unresponsive in bed. No prior symptoms. No chest pain before sleep. His wife says he was “making strange sounds” for about thirty seconds before she was fully awake. By the time EMS arrived, he was pulseless. They shocked him once. He came back.

In the emergency department, his blood pressure is 118 over 74. His rhythm is sinus. His troponin is undetectable. His echocardiogram shows a structurally normal heart. The coronary CT angiogram is clean.

Then someone runs a 12-lead ECG with right precordial lead placement, and the coved ST elevation in V1 and V2 is unmistakable. Type 1. Spontaneous. No fever. No medication provocation needed.

The cardiology fellow who sees the tracing knows immediately what this is. So does the patient’s mother, when she arrives at the hospital an hour later. Her brother died in his sleep at 31. The family never knew why.

This is Brugada syndrome. Not a rare academic curiosity. Not a footnote in the channelopathy chapter. The syndrome kills young men in their sleep in numbers large enough to have a name in Thai culture: Lai Tai. In Filipino culture: Bangungut. In Japanese epidemiology: Pokkuri. The same phenomenon, the same ECG, the same gene, recognized across continents before molecular cardiology existed to explain it.

The mechanism involves a sodium channel. The risk peaks at rest, at night, when vagal tone is highest. A fever can tip the balance. So can a handful of common drugs. The ECG can be normal one day and diagnostic the next. The distinction between “Brugada pattern” and “Brugada syndrome” is not a semantic quibble. It is a clinical decision with life-or-death stakes.

What It Is

Brugada syndrome is an inherited cardiac channelopathy characterized by a specific ECG pattern in the right precordial leads and an increased risk of ventricular fibrillation (VFib) and sudden cardiac death in the absence of structural heart disease. It was formally described in 1992 by Pedro and Josep Brugada (Brugada P and Brugada J, JACC 1992; DOI: 10.1016/0735-1097(92)90253-J).

The condition is inherited in an autosomal dominant pattern with incomplete penetrance. Approximately 20 to 25 percent of cases carry an identifiable pathogenic variant in SCN5A, the gene encoding the alpha-subunit of the cardiac sodium channel (Nav1.5) 5 / Solid . The remaining 75 to 80 percent of cases have no identifiable genetic cause by current testing, though variants in other genes affecting sodium channel function (SCN1B, SCN2B, GPD1L, CACNA1C, CACNB2) account for a small additional proportion 4 / Promising .

The Pattern vs. The Syndrome

This distinction is not optional.

The Type 1 Brugada ECG pattern is a specific morphology: a coved (downsloping) ST-segment elevation of at least 2 mm in one or more right precordial leads (V1-V3), followed by a negative T wave. It can be present spontaneously or only unmasked during pharmacologic provocation.

Brugada syndrome requires the Type 1 pattern plus at least one of the following: documented VFib or ventricular tachycardia (VT), a family history of sudden cardiac death at age under 45 in a first-degree relative with the Type 1 pattern, nocturnal agonal respirations, or inducible VFib at electrophysiology study 5 / Solid .

A person can have the Type 1 ECG pattern without meeting criteria for Brugada syndrome. They are not the same risk category. Conflating them leads to both overtreatment and undertreatment.

The Two Forms of the Type 1 Pattern

Spontaneous Type 1: The coved pattern is present on a resting ECG without provocation. This is the higher-risk form. Among patients who have experienced VFib, most showed spontaneous Type 1 at some point.

Drug-induced (unmasked) Type 1: The pattern appears only during sodium channel blocker challenge (ajmaline, flecainide, procainamide, or pilsicainide). A patient may have a normal resting ECG, and the sodium channel blocker uncovers the pattern by further reducing sodium current reserve, which shifts the balance between the right ventricular epicardium and endocardium.

The old Type 2 and Type 3 patterns (saddle-back configurations) are no longer used in the 2013 consensus classification. They are described as “Brugada pattern” when present but require sodium channel blocker challenge to confirm whether they convert to the diagnostic Type 1.

The Mechanism

The Sodium Channel and Nav1.5

The cardiac sodium channel Nav1.5 drives the rapid upstroke of phase 0 of the cardiac action potential. It opens briefly at the start of depolarization, admits a fast inward sodium current, and then inactivates rapidly. This fast inward current (I_Na) is the engine of rapid conduction through the His-Purkinje system and ventricles.

In Brugada syndrome, SCN5A mutations cause loss of function in Nav1.5. The channel may fail to open normally, inactivate too quickly, or traffic abnormally to the cell membrane. The result is a reduction in the fast inward sodium current 5 / Solid .

The Phase 2 Reentry Theory

The right ventricular epicardium has a distinctive ion channel balance: prominent transient outward potassium current (I_to) and a relatively weaker I_Na compared to the endocardium. When I_Na is reduced further (by SCN5A mutation, sodium channel blockers, fever, or autonomic changes), the action potential in the epicardium can lose its plateau phase entirely. The endocardium retains its plateau. This creates a voltage gradient between epicardium and endocardium that appears as ST-segment elevation in V1-V3.

The dispersion of repolarization within the right ventricular wall then provides the substrate for phase 2 reentry: a propagating wavefront that circles within the wall and triggers VFib 5 / Solid .

This explains several clinical features:

• The ECG changes are most visible in the right precordial leads (V1-V3), reflecting right ventricular epicardial involvement.
• Conditions that further reduce I_Na (fever, sodium channel blockers, vagal surge) precipitate events.
• The right precordial leads recorded at the 2nd or 3rd intercostal space (one or two spaces higher than standard) have higher sensitivity for the Type 1 pattern because they are positioned closer to the right ventricular outflow tract epicardium.

Fever as a Trigger

High body temperature reduces sodium channel availability through temperature-dependent kinetics. In SCN5A mutation carriers, even modest fever can push I_Na below the threshold needed to maintain the epicardial action potential plateau, converting a silent Brugada ECG into a Type 1 pattern and triggering VFib 5 / Solid .

This is a clinical emergency. Any patient with known Brugada syndrome who presents with fever and syncope, or is found unresponsive during febrile illness, must be evaluated immediately for arrhythmia. Antipyretics should be given aggressively. Admission for monitoring is appropriate.

Case series have documented VFib during febrile illness in patients who had previously been asymptomatic 4 / Promising .

Autonomic Modulation and the Nocturnal Pattern

Vagal tone slows heart rate and reduces sympathetic suppression of I_to. At rest and during sleep, when vagal tone peaks, the ionic balance tips further toward reduced sodium current and enhanced outward current. This is the mechanistic basis for the nocturnal predominance of events in Brugada syndrome.

Men have higher I_to density in the right ventricular epicardium than women. This is the leading explanation for the 8:1 male predominance in symptomatic Brugada syndrome 5 / Solid . Testosterone appears to upregulate I_to channels; estrogen may have a protective effect on the sodium channel. Post-menopausal women have slightly higher event rates than premenopausal women, consistent with this model 3 / Early .

Quinidine, which blocks I_to in addition to its sodium channel effects, is the pharmacological rationale for the only drug that reduces VFib inducibility in Brugada syndrome.

How We Diagnose

The 12-Lead ECG

The first requirement is recognizing the Type 1 pattern. It is not a subtle finding when present. Coved ST elevation: horizontal-to-downsloping ST segment, at least 2 mm of elevation at the J-point or J-wave in V1 or V2, with a negative T wave. No saddle-back confusion with the Type 1: it descends directly toward the isoelectric line without a terminal positive deflection.

Right precordial lead positioning matters. Standard V1 and V2 are placed at the 4th intercostal space. Moving these leads one or two intercostal spaces superiorly (to the 2nd or 3rd space) increases sensitivity significantly, because the right ventricular outflow tract (RVOT) is a superior structure 5 / Solid . Clinical protocols should specify which lead position was used when recording the tracing.

Serial ECGs help because the pattern is dynamic. A patient may have a normal ECG on one visit and a Type 1 pattern on another, particularly if the intervening period included fever, alcohol, or sleep deprivation.

The Sodium Channel Blocker Provocation Test

When the resting ECG does not show a spontaneous Type 1 pattern but clinical suspicion is high (family history of sudden death, personal history of unexplained syncope, palpitations, or resuscitated cardiac arrest), a pharmacologic challenge is appropriate.

The agents in use are:

• Ajmaline (1 mg/kg IV over 5 minutes): the standard in Europe and widely used in Asia; highest sensitivity
• Flecainide (400 mg oral or 2 mg/kg IV): widely used in the United States
• Procainamide (10 mg/kg IV over 10 minutes): available but lower sensitivity
• Pilsicainide: used primarily in Japan

The test must be performed in a monitored setting with resuscitation equipment available. VFib provocation, though rare, has been reported 4 / Promising .

A positive test converts a non-diagnostic ECG to a Type 1 Brugada pattern. It does not, by itself, establish Brugada syndrome. The clinical context, family history, and symptoms determine whether the full syndrome diagnosis applies.

Genetic Testing

SCN5A genetic testing is clinically available and recommended as part of the evaluation when Brugada syndrome is suspected 5 / Solid . However, a negative genetic test does not exclude Brugada syndrome. Approximately 20 to 25 percent of cases carry an SCN5A variant; the rest have no identifiable pathogenic variant with current panel testing.

A positive SCN5A variant of uncertain significance (VUS) does not confirm Brugada syndrome. Genetic counseling is essential before and after testing.

Family Screening

First-degree relatives of a patient with confirmed Brugada syndrome should be screened with a 12-lead ECG (at rest, in high precordial positions). If the resting ECG is non-diagnostic and clinical suspicion is present, sodium channel blocker challenge is appropriate. Genetic cascade testing is appropriate when a pathogenic SCN5A variant has been identified in the proband.

Electrophysiology Study (EPS)

The role of programmed electrical stimulation (PES) in Brugada syndrome risk stratification remains one of the most contested questions in electrophysiology. The debate is covered in Section 7.

The Evidence

Natural History and Risk Stratification

The published event rates vary substantially by study design and patient selection, which accounts for much of the controversy about risk stratification.

The PRELUDE registry (2012) followed 308 patients with Brugada syndrome and found that spontaneous Type 1 pattern and prior syncope were the strongest predictors of arrhythmic events 5 / Solid .

The FINGER registry (2010), the largest prospective cohort at the time with 1,029 patients, found that inducibility at EPS did not predict events in asymptomatic patients, challenging the prior consensus that EPS should guide ICD decisions 5 / Solid .

ICD Evidence

There is no randomized controlled trial comparing ICD versus no ICD in Brugada syndrome. The evidence base rests on registries, observational cohort data, and consensus extrapolation from other channelopathies.

For symptomatic patients with prior documented VFib or hemodynamically significant VT, ICD implantation is Class I 5 / Solid . This is non-controversial.

For symptomatic patients with syncope presumed arrhythmic in etiology (without documented arrhythmia), ICD is Class IIa. The difficulty is distinguishing vasovagal syncope from arrhythmic syncope in this population: both are common in young adults and both can occur in Brugada patients.

For asymptomatic patients with spontaneous Type 1 pattern, ICD is Class IIb. The data show the event rate is low enough (0.5 to 1% per year) that ICD complications (lead failure, inappropriate shocks, infection) may offset or exceed benefit in many individuals. This is the heart of the controversy covered in Section 7.

For asymptomatic patients with only drug-induced Type 1 pattern, ICD is generally not recommended. The annual event rate in this group is below 0.1%, and ICD-related complication rates over a decade would likely exceed the arrhythmia risk 5 / Solid .

Quinidine

Quinidine is the only pharmacologic agent with consistent data showing reduction of VFib inducibility in Brugada syndrome. Its mechanism is dual: blockade of I_to (the outward current that creates the phase 2 disparity in the RV epicardium) and, to a lesser degree, sodium channel effects.

A meta-analysis of quinidine use in Brugada syndrome found that VFib episodes were reduced in patients already implanted with ICDs, and that the drug was used as a “bridge” in patients with recurrent ICD shocks (VFib storm) awaiting more definitive management 4 / Promising .

Quinidine carries a Class IIb recommendation for asymptomatic patients with spontaneous Type 1 pattern who are being considered for long-term pharmacologic management in lieu of ICD, or in patients who decline ICD. It is not currently considered first-line empiric therapy for all Brugada patients 5 / Solid .

Practical obstacles: quinidine is difficult to obtain in some regions of the United States, is not stocked at many retail pharmacies, and requires monitoring for QTc prolongation and diarrhea (the most common reason patients discontinue it).

Catheter Ablation

Epicardial ablation of the right ventricular outflow tract (RVOT) has emerged as a promising strategy for patients with recurrent VFib storms or those who cannot tolerate or decline ICD. The RVOT epicardium contains the arrhythmogenic substrate: the zone of late potentials and abnormal electrograms that initiate phase 2 reentry.

The BRUGADA-ABORT trial and several single-center series have demonstrated normalization of the Brugada ECG pattern after epicardial RVOT ablation and reduction of VFib recurrence over follow-up periods of 2 to 4 years 4 / Promising . Longer-term data and multicenter experience are accruing.

This approach is currently available at high-volume electrophysiology centers, not at community hospitals. Northwestern Medicine (Chicago), Mayo Clinic (Rochester), University of Michigan (Ann Arbor), and Vanderbilt University are among the centers with published epicardial ablation programs. Referral from regional centers, including Carle Foundation Hospital in Urbana, Illinois, is appropriate for patients in VFib storm.

Subcutaneous ICD (S-ICD)

The subcutaneous ICD (Boston Scientific EMBLEM S-ICD) is an option in Brugada syndrome patients who need arrhythmia protection but do not need anti-bradycardia pacing or ATP (anti-tachycardia pacing). Because VFib in Brugada is not typically preceded by a monomorphic VT amenable to ATP, the S-ICD is a reasonable choice in younger patients.

The S-ICD avoids transvenous lead complications (lead fracture, endocarditis, venous occlusion) that accumulate over decades in young patients. However, it cannot treat polymorphic VT or provide backup pacing. Sensing vector screening is mandatory before implant: the Brugada ECG changes in V1-V2 can cause T-wave oversensing and inappropriate shocks if the wrong sensing vector is programmed 5 / Solid .

The Patient Experience

What It Feels Like to Have Brugada Syndrome

Many patients with Brugada syndrome have had no symptoms at all before diagnosis. They learn about their condition through one of three routes: a family member’s sudden death prompts cascade screening; a routine or pre-operative ECG shows an unexpected pattern; or they experience an episode of syncope or a resuscitated cardiac arrest that triggers the workup.

The experience of receiving the diagnosis differs depending on the route.

The person who learns about Brugada through family screening may feel ambushed by a condition they associate with their relative’s death, while facing the uncertainty of not knowing whether they themselves will ever have an event. The statistical reassurance (“your annual risk may be less than 0.5%”) does not land the same way for everyone. Some patients will want an ICD because the idea of uncertainty is intolerable. Others will decline, because they have read the data and concluded that the risk of device complications over thirty years does not favor implantation for their specific situation. Both are rational positions when the evidence genuinely supports more than one choice.

The person who survives a cardiac arrest finds the context starkly different. They have been resuscitated. They know what the worst-case scenario looks like because they came within moments of it. For them, the ICD is not a statistical exercise. The calculus is different.

Palpitations, Syncope, and Arrhythmia Fear

Palpitations are common in the general population and are not a specific symptom of Brugada syndrome. However, after diagnosis, palpitations take on a new meaning. Every skipped beat prompts a question that was not there before. This is not irrational. It is a predictable consequence of learning that one’s cardiac rhythm can become lethal without warning.

Syncope in a Brugada patient should be treated as arrhythmic until proven otherwise. This is not the approach to syncope in the general population (where vasovagal is overwhelmingly the most common cause), but the conditional probability of malignant VT/VFib causing syncope in a known Brugada patient is high enough to change the differential.

The sleep disruption is real. Some patients, particularly those diagnosed after a nocturnal event, will be anxious about sleeping. Partners of Brugada patients describe the strange vigilance of sleeping next to someone with a condition that strikes at night. The ICD, paradoxically, may improve sleep quality by providing a “back-up” even though the device cannot prevent every arrhythmia.

Drugs to Avoid

Every Brugada patient should carry a list of contraindicated medications. The Brugada drugs database (available at brugadadrugs.org) organizes agents by risk level. The highest-risk category includes:

• Sodium channel blockers used as antiarrhythmics (flecainide, propafenone, ajmaline, procainamide, disopyramide)
• Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline)
• Certain antihistamines (diphenhydramine in high doses; dimenhydrinate)
• Some psychotropic agents (lithium at toxic levels; certain phenothiazines)

Patients should present this list to any clinician prescribing a new medication, including emergency physicians who may not be familiar with Brugada syndrome. The list should be updated as the evidence base evolves. A single Brugada-pattern ECG documented in the medical record is not sufficient protection if a covering physician does not check the database.

Cocaine use can unmask or exacerbate the Brugada ECG pattern and has been associated with VFib in the setting of known Brugada syndrome 4 / Promising .

Fever management at home: patients should monitor temperature during illness and take antipyretics (acetaminophen or ibuprofen) early when fever develops. Any fever above 38.5 degrees Celsius in a Brugada patient warrants close monitoring, and any associated syncope or near-syncope should prompt immediate emergency evaluation.

Lifestyle and Activity

No randomized trial exists to define activity restrictions in Brugada syndrome, and current guidelines do not uniformly restrict competitive athletics in asymptomatic Brugada patients with drug-induced Type 1 pattern only. However, the 2015 AHA/ACC scientific statement on competitive athletes with arrhythmias noted that patients with spontaneous Type 1 pattern and prior cardiac events should be restricted from competitive sports pending ICD implantation and, ideally, a period of stable follow-up 5 / Solid .

Alcohol and sleep deprivation, both of which can increase vagal tone and unmask the Brugada ECG pattern, should be avoided or minimized. Large meals, particularly carbohydrate-heavy meals in the evening, may transiently increase vagal tone.

The geographic distribution of Brugada syndrome follows patterns of SCN5A founder effects. Southeast Asian populations (particularly from Thailand, the Philippines, Japan, and Laos) have the highest known prevalence, estimated at 5 to 20 per 10,000 in some regions 5 / Solid . In the United States, the overall prevalence is estimated at 1 to 5 per 10,000, with higher rates in populations with Southeast Asian heritage.

Decisions and Trade-Offs

The Hardest Question in Brugada Syndrome: What to Do with the Asymptomatic Patient

A 28-year-old man, no symptoms, is screened after his older brother’s sudden death. His ECG shows spontaneous Type 1 Brugada pattern in high right precordial leads. His genetic test returns a pathogenic SCN5A variant. He runs five miles per week, works as a software engineer, and has three young children. He asks you: “Doctor, do I need the ICD?”

This is the question that occupies the electrophysiology community. There is no clean answer, and the guidelines say so explicitly.

The arguments for ICD implantation in this scenario:

• Spontaneous Type 1 pattern carries annual risk of VFib around 0.5 to 1 percent
• Over 30 years of life expectancy, the cumulative risk is not trivial
• His brother’s death establishes that his family carries an arrhythmogenic phenotype
• The ICD is the only therapy with unambiguous efficacy for terminating VFib

The arguments against:

• Annual risk of 0.5 to 1 percent means over 100 to 200 years would pass before the average such patient has an event
• Lead complications accumulate: lead fracture, infection, venous occlusion, inappropriate shocks (which carry their own morbidity and mortality)
• A 28-year-old with a transvenous ICD will need at least 3 to 5 pulse generator replacements and possibly lead revisions over his lifetime
• Inappropriate shocks occur in 10 to 20 percent of ICD patients over long follow-up; each shock is a psychological event even when appropriate
• The FINGER registry found that EPS inducibility did not predict events in asymptomatic patients 5 / Solid

What the 2013 HRS/EHRA/APHRS consensus says: ICD is Class IIb for asymptomatic patients with spontaneous Type 1 Brugada pattern. This is the weakest recommendation class that still permits the intervention.

The practical approach at most centers: shared decision-making with written documentation. The electrophysiologist presents the annual event rate, the lifetime complication burden of an ICD, the alternatives (quinidine, watchful waiting, S-ICD if the patient eventually chooses device therapy), and the patient decides in alignment with his values and tolerance for each type of risk.

EPS is sometimes performed to determine inducibility with the goal of refining risk stratification, but the FINGER data have reduced enthusiasm for this approach in asymptomatic patients. Some centers still use EPS for intermediate-risk patients; others have moved away from it entirely for this indication.

Sex Differences

Men are diagnosed with symptomatic Brugada syndrome approximately 8 times more often than women 5 / Solid . This is not a screening bias: even in population-based studies with equivalent ECG evaluation, men show the pattern far more frequently and have far more arrhythmic events.

The mechanism is believed to involve sex steroid effects on I_to density in the RV epicardium. Testosterone upregulates I_to; estrogen may downregulate it or provide protection through other mechanisms. Men who undergo androgen deprivation therapy (for prostate cancer) may experience attenuation of the Brugada ECG pattern, supporting this model 3 / Early .

Women with Brugada syndrome do have events. The annual event rate in symptomatic women is similar to that in symptomatic men. The key difference is that fewer women reach the symptomatic threshold.

Post-menopausal women with known Brugada pattern may have a modestly higher event rate than premenopausal women, consistent with the hormonal model 3 / Early . This has not yet changed guideline recommendations for women, but clinicians should be aware of the data.

The Drug Interaction Problem in Practice

Polypharmacy creates compounding risk. A Brugada patient who is admitted to a general medicine floor for pneumonia may receive:

• Azithromycin (mild sodium channel effects at standard doses; evidence is mixed but it appears on the risk list)
• A NSAID with sodium-channel-blocking properties
• A single dose of diphenhydramine for insomnia

None of these alone would be alarming. In a Brugada patient with spontaneous Type 1 and a borderline sodium channel reserve, the combination during a febrile illness may be sufficient to precipitate VFib.

The practical solution is an alert in the electronic health record (EHR) and patient-carried documentation. For patients who travel internationally, a medical summary card in their language, with the brugadadrugs.org reference, should be standard.

Anesthesia and Surgery

Certain anesthetic agents can unmask or exacerbate the Brugada ECG pattern. Propofol has been associated with Brugada pattern induction and VFib events 4 / Promising . Bupivacaine (a sodium channel blocker used in regional anesthesia) is contraindicated. Anesthesiologists managing a Brugada patient should have the sodium channel blocker contraindication list and should avoid propofol when an alternative induction agent is available.

Pregnancy

Pregnancy does not appear to increase Brugada arrhythmia risk significantly, based on limited case series. Hormonal changes in pregnancy include higher progesterone levels, which may have protective effects on the sodium channel. Most women with Brugada syndrome who have been followed through pregnancy without ICD have not experienced events 3 / Early . However, epidural anesthesia with bupivacaine is contraindicated; alternatives (lidocaine epidural, spinal with hyperbaric bupivacaine in very low dose) are used by experienced obstetric anesthesia teams.

Clinical Synthesis

Brugada syndrome is one of the few cardiac conditions where the ECG carries more information than the symptom history. A man can feel completely well, run five miles, sleep without interruption, and carry an arrhythmia substrate that could kill him on any given night without warning. The ECG, not the story, is where this diagnosis lives.

The clinical thesis holds that most cardiovascular deaths are not random. They follow from identifiable biology, identifiable triggers, and identifiable treatment gaps. Brugada syndrome fits this model precisely. The gene is identifiable. The provocative conditions (fever, sodium channel blockers, vagal surge at night) are identifiable. The family history is a neon signal that something runs in the bloodline. The deaths in Southeast Asian communities that were attributed to supernatural causes for generations were Brugada syndrome, and they were diagnosable on a $50 ECG.

The detection gap is real. Brugada syndrome remains underdiagnosed in primary care settings. General internists and family physicians who encounter an unusual-looking V1-V2 on a routine ECG may not recognize the Type 1 pattern. It may be attributed to normal variant, Brugada “look-alike” conditions (RBBB, early repolarization, pericarditis), or simply not flagged. The patient walks out, unaware.

For the patient who comes in for an audit with a family history of sudden death at a young age in a male relative, the ECG should include right precordial leads placed at the 2nd and 3rd intercostal space, not just standard position. This is not standard in most clinic ECG protocols. It should be.

For the patient who is a Southeast Asian man, or who has a family history of nocturnal sudden death, the algorithm should include Brugada syndrome screening even in the absence of symptoms. The cost of a high-precordial ECG is zero. The cost of missing the diagnosis can be everything.

Routing:

• Suspected Brugada pattern on ECG: refer to electrophysiology for formal evaluation and sodium channel blocker challenge if indicated.
• Confirmed Brugada syndrome with prior cardiac arrest: ICD implantation at a high-volume EP center. Northwestern Medicine, University of Chicago, or University of Illinois Chicago for the Chicago metro. Carle Foundation Hospital in Urbana coordinates referral to Champaign-Urbana area patients.
• Asymptomatic Brugada pattern with strong family history: EP consultation for shared decision-making regarding risk stratification and ICD discussion.
• VFib storm or recurrent ICD shocks: consider referral to a center with epicardial ablation program.
• Known Brugada patient presenting with fever: aggressive antipyretics, continuous monitoring, lower threshold for hospital admission.

Brugada syndrome is not rare in the populations that carry it. It is underdiagnosed in the clinical systems that should find it. The ECG is the test. The high precordial lead position is the technique. The electrophysiologist is the next step.

The night carries the risk. The ECG holds the answer. The time to look is now, before the 3 AM call that starts this story.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.